large cohort study of CDK 4/6 BRAF EGFR VEGF and other cancer treatments #OncoNephrology #NephSky #KidneyWk jamanetwork.com/journals/jam... from Shuchi Anand et al from @stanfordmedicine.bsky.social

Now live in #ASNJASN, simultaneously published with #KidneyWk: "Immunosuppression in Older Kidney Transplant Recipients: A Randomized Controlled Trial" Read more: kidney.pub/JASN0924

Among more than 800 000 CKD-PC participants, discordance between cystatin C and creatinine eGFR values was associated with increased risk of death, cardiovascular events, and kidney failure. #KidneyWK @asnkidney.bsky.social ja.ma/4oV4DtU

In celebration of #KidneyWk, the entire November issue is FREE to access until November 30, 2025! Check out the plain-language summaries on what inspired each study, the basic approach taken, what was learned, and why it matters: bit.ly/3X1XpZj

Thoughtful and controversial blog from Last Month in Nephrology #NephSky #MedSy Albuminuria as an ESKD surrogate may be a statistical mirage, limited by imprecision and overinterpretation However, it moved nephrology forward and made studies happen lastmonthinnephrology.wordpress.com

🤔 How often is end-stage kidney disease in patients with MCD/ FSGS? #NephSky #MedSky @brianrifkin.bsky.social dissected the conclusions from the RaDar study in this #NephJCshorts *the original article from @asnpublications.bsky.social www.nephjc.com/news/nephjc-...

On 7/22/25 at 9pm EST only on Bluesky! #NephSky #MedSky join us for a lively discussion. We're debating eGFRdiff (the gap that is sometimes present between the eGFR of cystatin C and creatinine). What does it mean, what causes it and what you should do about it. #NephJC www.nephjc.com/news/egfrdiff

Read this piece from the ERAKI working group at the @ndt-era.bsky.social regarding the results of the DEFENDER trial published last August @jama.com academic.oup.com/ndt/article/...

We don’t get to discuss every important study that comes out on #NephJC Hence #NephJCShorts www.nephjc.com/news/nephjc-...

Enjoy the latest edition of ISN-ACT Global Trials Focus (GTF), a monthly list identifying and summarizing recent interesting trials relevant to kidney disease. Each trial is reviewed in context and assessed for its risk of bias in key areas ➡ http://lite.spr.ly/6...

On the #AJKDBlog, catch up on these interviews with: - Oshozimhede E. Iyalomhe on statin use in CKD - Roger Rodby and William Whittier about renal tubular acidoses - Subhash Chander on urea as a tool for managing SIADH-induced hyponatremia bit.ly/3ztk4VV (FREE)

Dr. Katherine Tuttle focuses her educational Grand Rounds talk on a reemerging topic: "New Approaches to Blocking #Aldosterone & #Angiotensinogen for #Hypertension or #CKD." #kidney #nephrology #nephsky @uwmedicine.bsky.social youtu.be/TeWkmCopuzk

When @rajmehrotra.bsky.social is giving a talk on the factors for home dialysis stagnation and growth in US at the #CSNAGM We get to see a CJASN abstract! From Divya Bajpai

📣 Reminder! ASDIN is accepting applications for the $25K Research Grant in Vascular Access — but don’t wait! 🗓 Applications close July 15, 2025. Click here to learn more: www.asdin.org/news/699844/... #vascularaccess #ASDIN #researchgrant #nephrology

Use of SGLT2 inhibitors (SGLT2i) in ADPKD is not "presently" recommended, because people with ADPKD have been excluded from the clinical trials; thus, its safety has not been evaluated (from @kdigo.org) #Nephpearls #NephSky 👉 kdigo.org/guidelines/a...

Finerenone reduced kidney and cardiovascular events in CKD and T2D patients, regardless of frailty. Benefits included lower albuminuria and slower eGFR decline, supporting its use even in frail individuals. #podocytetalk #Nephpearls #Nephrology #CKD journals.lww.com/cjasn/abstra...

Sparsentan is now approved for the treatment of IgAN in European Union countries. #igan #iganephropathy #kidneydisease #nephrology #nephsky www.docwirenews.com/post/eu-appr...

SGLT2 Inhibitors and Risk for Hyperkalemia Among Individuals Receiving RAAS Inhibitors jamanetwork.com/journals/jam...

Do you prescribe SGLT2 inhibitors (SGLT2i) for patients with ADPKD? #Nephpearls #AskRenal #NephSky ❤️ LIKE for YES (and why?) ❌ X for NO (and why?) 👉 pubmed.ncbi.nlm.nih.gov/39099568/

Do you allow hemodialysis patients with permanent HD catheters to shower? Yes No Other, please state www.ajkd.org/article/S027... #nephinp #nephrology_in_practice @ajkd.bsky.social

Progress, challenges, and pragmatic concessions in predicting relative risk of kidney survival in ARPKD doi.org/10.1016/j.kint.2025.02.018 Original article: doi.org/10.1016/j.kint.2025.01.023 #KICommentary #MedSky #NephSky #polycystickidneydisease

Alternative complement pathway dysregulation in CKD and CKD progression, endothelial inflammation and cardiovascular outcomes… room for complement inhibitors beyond complement-mediated kidney diseases? www.jci.org/articles/vie... #NephSky #MedSky

Editorial by Harshil A. Fichadiya and John C. Lieske: Do Topiramate and Zonisamide Cause Kidney Stones? bit.ly/FichadiyaED25 (FREE)

#KIControversies in Nephrology Clinical utility of donor-derived cell-free DNA 🧬testing for kidney transplant monitoring in selected patients You can read the ✅Point ✅Counterpoint ✅Editor's summary in the May issue of KI doi.org/10.1016/j.kint.2025.01.039 #MedSky #NephSky #kidneytransplant

When to use spironolactone, eplerenone or finerenone in the spectrum of cardiorenal diseases academic.oup.com/ndt/article/... An amazing article from the high impact articles published by @ndt-era.bsky.social

Stopping Versus Continuing Metformin in Patients With Advanced CKD: A Nationwide Scottish Target Trial Emulation Study bit.ly/3ZdrYxb #OpenAccess #VisualAbstract #CKD

Despite my ranking, I am still getting both winners at the finals.. @nephmadness.bsky.social

And I did that in 2016 in response to Dr Rodby’s decisions Funnily, today he agrees with me over on Xitter that this was a giant #BlueRibbonFail #NephMadness

What is the impact of retracted studies being cited in systematic reviews? Cool study in @jama.com IM jamanetwork.com/journals/jam... Even cooler: ‘feet of clay’ detector from @gcabanac.cpesr.fr used here dbrech.irit.fr/pls/apex/f?p... #MedSky #EpiSky

The April issue of JASN is now available online! Topics covered this month include: - Novel Therapies for IgA Nephropathy - Rituximab in Podocytopathies - and more Find the issue here: journals.lww.com/jas... #ASNJASN

Results of the first round are up @nephmadness.bsky.social #nephsky Excellent results for @nephsim.bsky.social 8/8

Check my latest editorial @kidney360 journals.lww.com/kidney360/fu...

What other Landmark Trials in ADPKD should be included in this list⁉️ #Nephpearls #NephJC #NephSky ⏹️ CRISP pubmed.ncbi.nlm.nih.gov/16707749/ ⏹️ Everolimus pubmed.ncbi.nlm.nih.gov/20581392/ ⏹️ TEMPO 3:4 pubmed.ncbi.nlm.nih.gov/23121377/ ⏹️ HALT A pubmed.ncbi.nlm.nih.gov/25399733/ ⏹️ HALT B ⏹️ REPRISE

The ASN Journal Portfolio seeks early career scientists and junior faculty members interested in participating in the editorial process of peer reviewed journals to join our Junior Associate Editor (JAE) Program. Learn more and apply by May 2. bit.ly/TraineePrograms @rajmehrotra.bsky.social

Trials of #SGLT2 inhibitors dapagliflozin and empagliflozin have shown renal benefits, but those trials excluded patients with #ADPKD. #nephrology #nephsky #kidneydisease

The draft Scope of Work for the KDIGO 2025 B Cell–Mediated Therapies Controversies Conference is open for public comment through April 21. Download the SOW and submit feedback via the form on the conference site: kdigo.org/conferences/... #BCell

⚠️ The FDA has approved oral iptacopan to treat proteinuria in adults with C3 glomerulopathy. This is the first FDA-approved treatment for C3G. #fda #c3glomerulopathy #c3g #kidneydisease #nephrology #nephsky

Happening this week! The @kdigo.org guidelines in #ADPKD #PKD on #NephJC www.nephjc.com/news/adpkd-k... Summary from @brianrifkin.bsky.social

A new trial published @ndt-era.bsky.social assessing a new device integrated in the PD cycler for remote monitoring of automated PD, whether it will improve clinical outcomes or not.

Still anyone thinking #denervation will do better than #noveantiHTNmedications?! in the first round of @nephmadness.bsky.social #trashtalks #nephmadness #Noveltreatments FTW!

I am "CONVINCE"D that #hemodiafiltration will overcome #incrementalhemodialysis in the @nephmadness.bsky.social match on the first round. you will be lost if you chose #incrementalHD #trashtalk #nephmadness or may be the #blueribbonfail are not yet "CONVINVE"D !!

Thanks for the tip off @robertbrownpharm.bsky.social - sharing for any others who might find this useful #pharmsky #nephsky #medsky

we have reached the point where we seriously should avoid travelling to the US Sorry @asnkidney.bsky.social @ahascience.bsky.social @kidneycon.bsky.social #NephSky

Nice blurb in @asnkidney.bsky.social in the loop about the CRRT curriculum in @ajkd.bsky.social Free link (few more weeks, download now) authors.elsevier.com/sd/article/S... Thanks to @nephcrit.bsky.social & Ted Clark for helming this & @melhoenig.bsky.social for the invite! #NephSky #Free

Combination therapy: an upcoming paradigm to improve kidney and cardiovascular outcomes in chronic kidney disease 🆓 doi.org/10.1093/ndt/...